Literature DB >> 1898714

Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II).

C C Chao1, Y L Lee, P W Cheng, S Lin-Chao.   

Abstract

Human HeLa cells resistant to cisplatin were established by stepwise selection. The selected cells showed a 15- to 20-fold cisplatin resistance (CPR) at the dose level resulting in 50% inhibition. These cells were cross-resistant to mitomycin C, melphalan, and ethyl methanesulfonate but not to Adriamycin, colchicine, or vinblastine. The expression of cisplatin-damaged plasmid DNA carrying the bacterial chloramphenicol acetyltransferase (CAT) gene after its transfection into CPR cells was enhanced by approximately 3-fold. This did not correlate with the degree of CPR. However, the development of the CPR phenotype paralleled the enhanced CAT activity. The addition of aphidicolin (an inhibitor of DNA alpha-polymerase) to CPR cells effectively diminished the enhanced CAT activity and CPR. These studies have identified an enhanced host cell reactivation of the damaged plasmid in the acquisition of CPR, suggesting that DNA repair is a potential mechanism for the development of CPR phenotype in human cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898714

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Co-variation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme.

Authors:  X Y Hao; M Widersten; M Ridderström; U Hellman; B Mannervik
Journal:  Biochem J       Date:  1994-01-01       Impact factor: 3.857

2.  Characterization of a DNA-damage-recognition protein from F9 teratocarcinoma cells, which is inducible by retinoic acid and cyclic AMP.

Authors:  C C Chao; N K Sun; S Lin-Chao
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

Review 3.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Cross-resistance to UV radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified DNA.

Authors:  C C Chao; S L Huang; H M Huang; S Lin-Chao
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  Damage-recognition proteins as a potential indicator of DNA-damage-mediated sensitivity or resistance of human cells to ultraviolet radiation.

Authors:  C C Chao
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

6.  Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein.

Authors:  S Keeney; A P Eker; T Brody; W Vermeulen; D Bootsma; J H Hoeijmakers; S Linn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling.

Authors:  Pachiyappan Kamarajan; Nian-Kang Sun; Chuck C-K Chao
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

8.  Ca(2+)-mediated inhibition of a nuclear protein that recognizes UV-damaged DNA and is constitutively overexpressed in resistant human cells: DNA-binding assay.

Authors:  C C Chao; S L Huang; S Lin-Chao
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

9.  Induction, not associated with host-cell re-activation of damaged plasmid DNA, of damaged-DNA-recognition proteins by retinoic acid and dibutyryl cyclic AMP in mammalian cells.

Authors:  N K Sun; S L Huang; S Lin-Chao; C C Chao
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

10.  Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II).

Authors:  C C Chao; S L Huang; L Y Lee; S Lin-Chao
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.